Study guide

7.1 Respiratory & Endocrine Therapeutics

PSI Equivalence Examination Third Country Qualification Recognition

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & TCQR Framework

1.1 TCQR Pathway and PSI Equivalence Exam Structure 1.2 PSI Core Competency Framework and MPharm Standard 1.3 Irish Healthcare System & Pharmacy Environment

2 Chapter 2: Pharmaceutical Calculations

2.1 Paediatric & Adult Dose Calculations 2.2 Percentage Strengths, Ratio Strengths & PPM Conversions 2.3 Dilutions, Alligations & Reconstitution 2.4 Infusion Rates, Syringe Drivers & Opioid Equianalgesic Conversions

3 Chapter 3: Pharmacology & Applied Pharmacokinetics

3.1 Receptor Pharmacology & Autonomic Nervous System 3.2 Cardiovascular & Renal Pharmacology 3.3 Central Nervous System & Antimicrobial Pharmacology 3.4 Pharmacokinetics & Narrow Therapeutic Index Drugs

4 Chapter 4: Basic Science & Pharmaceutics

4.1 Physicochemical Properties of Drugs 4.2 Dosage Form Formulation & Excipients 4.3 Drug Stability, Degradation & Bioequivalence

5 Chapter 5: Pharmacy Practice & Dispensing Workflow

5.1 Prescription Validation & Dispensing Workflow 5.2 Patient Counselling & Medicines Safety 5.3 Responding to Symptoms & Minor Ailments 5.4 Primary Care Schemes & Community Services

6 Chapter 6: Irish Pharmacy Law & Professional Ethics

6.1 Pharmacy Act 2007 & PSI Governance 6.2 Medicinal Products Regulations 6.3 Controlled Drugs Legislation & Misuse of Drugs Regulations 6.4 Professional Ethics & Code of Conduct

7 Chapter 7: Clinical Therapeutics & Disease State Management

7.1 Respiratory & Endocrine Therapeutics 7.2 Cardiovascular & Gastrointestinal Therapeutics 7.3 Infections, Antimicrobial Stewardship & Public Health 7.4 Special Populations & Complex Care

8 Chapter 8: OSCE & Practical Clinical Communication Skills

8.1 OSCE Station Structure & Core Competencies 8.2 Structured Patient Consultations & Devices Counselling 8.3 Prescriber Interventions, Ethical Dilemmas & Professional Judgement

7.1 Respiratory & Endocrine Therapeutics

Key Takeaways Explain This Topic AI

GINA guidelines recommend low-dose ICS-formoterol as the preferred reliever across all steps (Track 1 / MART), eliminating SABA-only monotherapy.

GOLD 2023/2024 guidelines classify COPD into Groups A, B, and E, using blood eosinophil counts (>=300 cells/µL) to guide initial ICS triple escalation.

Inhaler device selection requires matching patient inspiratory flow: DPIs need quick, deep inhalation (>60 L/min) while pMDIs require slow, steady technique with spacers.

Type 1 Diabetes management relies on basal-bolus insulin with carbohydrate counting; acute hypoglycemia (<4.0 mmol/L) is managed via the Rule of 15.

Type 2 Diabetes therapy prioritizes organ protection: SGLT2 inhibitors and GLP-1 RAs are recommended for patients with ASCVD, HF, or CKD regardless of baseline HbA1c.

Last updated: July 2026

7.1 Respiratory & Endocrine Therapeutics

Clinical therapeutics in primary care requires a deep understanding of evidence-based guidelines, disease pathophysiology, and individualized pharmacotherapy. This section details chronic management strategies for asthma, COPD, Type 1 Diabetes (T1DM), and Type 2 Diabetes (T2DM).

Asthma Step-Wise Management (GINA Guidelines)

The Global Initiative for Asthma (GINA) guidelines fundamentally restructured asthma care by moving away from Short-Acting Beta-2 Agonist (SABA) monotherapy. SABA-only treatment is associated with an increased risk of severe exacerbations and asthma-related mortality due to beta-receptor downregulation and unchecked underlying inflammation.

GINA defines two primary treatment tracks for adults and adolescents:

Track 1 (Preferred): Uses an anti-inflammatory reliever ( low-dose Inhaled Corticosteroid [ICS]-formoterol ) as needed across all steps. Formoterol provides rapid bronchodilation combined with simultaneous low-dose anti-inflammatory ICS delivery. This approach is Maintenance and Reliever Therapy (MART).

Track 2 (Alternative): Uses a SABA (salbutamol) reliever, paired with regular daily ICS maintenance therapy. Indicated only if Track 1 is not feasible.

  • GINA Step Track 1 (Preferred Treatment) Track 2 (Alternative Treatment)
  • Step 1 & 2 As-needed low-dose ICS-formoterol Regular low-dose ICS + as-needed SABA
  • Step 3 Low-dose maintenance MART Low-dose ICS-LABA + as-needed SABA
  • Step 4 Medium-dose maintenance MART Medium/High-dose ICS-LABA + as-needed SABA
  • Step 5 High-dose MART + LAMA or biologic High-dose ICS-LABA + LAMA or biologic + SABA
  • COPD Management (GOLD ABE Assessment & Escalation)

Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent airflow limitation. The GOLD framework stratifies patients into Groups A, B, and E based on symptoms (mMRC or CAT score) and exacerbation history.

GOLD ABE Classification Matrix

Group A: Low symptoms (mMRC 0-1, CAT <10) AND low exacerbation risk (0-1 moderate exacerbation, no hospital admission).

Group B: High symptoms (mMRC >=2, CAT >=10) AND low exacerbation risk (0-1 moderate exacerbation, no hospital admission).

Group E: High exacerbation risk (>=2 moderate exacerbations OR >=1 exacerbation leading to hospital admission). GOLD ABE PHARMACOTHERAPY INITIAL CHOICE

=======================================

  • Group A: Monotherapy (Bronchodilator: SABA, LABA, or LAMA)
  • |
  • Group B: Dual Bronchodilation (LABA + LAMA combination)
  • |
  • Group E: Initial Dual Bronchodilation (LABA + LAMA)
  • *If Blood Eosinophils >= 300 cells/µL -> Initial Triple (LABA + LAMA + ICS)
  • Role of Blood Eosinophils in ICS Escalation

ICS should not be used as monotherapy in COPD due to lack of efficacy and pneumonia risk. Blood eosinophil counts guide ICS addition to dual LABA+LAMA therapy:

Blood Eosinophils >=300 cells/µL: High likelihood of benefit; strongly supports adding ICS (Triple therapy: LABA + LAMA + ICS).

Blood Eosinophils 100-300 cells/µL: Moderate benefit; consider ICS if persistent exacerbations occur.

Blood Eosinophils <100 cells/µL: Low benefit; ICS escalation is not recommended.

Inhaler Device Selection & Technique Checks

Device selection must match patient cognitive capacity, dexterity, and peak inspiratory flow rate (PIFR).

Device Category Inspiratory Effort Required Operational Mechanism Spacer Compatible? Key Counselling Point

pMDI Low flow (30 L/min), slow & deep Propellant-driven aerosol spray Yes (AeroChamber) Press canister at start of slow inspiration; hold breath 10 sec.

DPI (e.g., Turbohaler, Ellipta) High flow (>60 L/min), quick & deep Passive breath-actuated dispersion No Inhale quickly and deeply; do not breathe out into device.

SMI (e.g., Respimat) Low flow, slow & deep Mechanical spring aerosolization Yes (with adapter) Turn, open, press button while taking slow deep breath.

Clinical Note: Patients using ICS devices must rinse their mouth with water and spit it out after every dose to prevent oral candidiasis and dysphonia.

Type 1 Diabetes Mellitus (T1DM)

T1DM requires lifelong insulin replacement due to autoimmune destruction of pancreatic beta cells.

Basal-Bolus Regimens & Carbohydrate Counting

Standard therapy consists of a basal-bolus regimen :

Basal Insulin: Once or twice daily long-acting insulin (degludec, glargine) suppresses hepatic glucose output overnight.

Bolus Insulin: Rapid-acting insulin (aspart, lispro) administered 5-15 minutes prior to meals for postprandial glucose control.

Patients calculate mealtime bolus doses using the Insulin-to-Carbohydrate Ratio (ICR) and correct hyperglycemia using the Insulin Sensitivity Factor (ISF) : Total Meal Bolus = ( Carbohydrates (g) ICR ) + ( Current BG − Target BG ISF ) \text{Total Meal Bolus} = \left( \frac{\text{Carbohydrates (g)}}{\text{ICR}} \right) + \left( \frac{\text{Current BG} - \text{Target BG}}{\text{ISF}} \right) Total Meal Bolus = ( ICR Carbohydrates (g) ​ ) + ( ISF Current BG − Target BG ​ )

  • Acute Hypoglycaemia Management (Rule of 15)
  • Hypoglycaemia is defined as blood glucose <4.0 mmol/L . HYPOGLYCAEMIA MANAGEMENT (RULE OF 15)
  • =====================================
  • Step 1: Administer 15-20g Fast-Acting Oral Carbohydrate
  • (e.g., 200 mL orange juice, 4-5 glucose tablets)
  • |
  • Step 2: Wait 15 minutes and re-check Blood Glucose
  • |

Step 3: Is Blood Glucose < 4.0 mmol/L?

  • ├── YES ──> Repeat Step 1 & re-check in 15 min
  • └── NO ──> Give 10-15g Complex Carbohydrate snack
  • (e.g., 1 slice of bread, 2 digestive biscuits)

Severe Hypoglycaemia (Unconscious): Administer IV 20% Glucose (75-100 mL) over 15 minutes, or IM Glucagon 1mg (or Nasal Glucagon 3mg ).

Type 2 Diabetes Mellitus (T2DM) Pharmacotherapy

Modern T2DM management prioritizes glycemic control alongside organ protection.

Drug Class Exemplars Primary Mechanism Clinical Benefits & Indications Key Risks & Monitoring

Biguanide Metformin Inhibits hepatic gluconeogenesis; enhances insulin sensitivity 1st-line for T2DM; weight neutral; non-hypoglycemic GI upset; lactic acidosis (hold if eGFR <30 mL/min); B12 deficiency.

SGLT2 Inhibitors Dapagliflozin, Empagliflozin Inhibits SGLT2 in renal tubule; increases glucosuria ASCVD, Heart Failure (HFrEF), CKD benefit regardless of HbA1c Genital infections, volume depletion, euglycaemic DKA.

GLP-1 Receptor Agonists Semaglutide, Dulaglutide Incretin mimetic: glucose-dependent insulin secretion ASCVD benefit , major weight reduction, low hypo risk Nausea, vomiting; pancreatitis risk.

DPP-4 Inhibitors Sitagliptin, Linagliptin Inhibits DPP-4, prolonging endogenous GLP-1 Weight neutral; Linagliptin safe in renal failure pancreatitis risk. Do NOT combine with GLP-1 RAs.

Sulfonylureas Gliclazide, Glimepiride Stimulates insulin release from beta cells Rapid HbA1c reduction; low cost High hypo risk , weight gain; adjust dose in renal impairment.

Glycemic Targets

Standard Target: <48 mmol/mol (6.5% - 7.0%) for most non-pregnant adults to minimize microvascular complications.

Relaxed Target: 53-58 mmol/mol (7.0% - 7.5%) in frail elderly patients or those with severe hypoglycemia history.